Candesartan cilexetil antihypertensive treatment attenuated SHR cardiac remodeling
Candesartan cilexetil antihypertensive treatment improved SHR mitochondrial morphology, structure, and function.
Candesartan cilexetil antihypertensive treatment improved SHR mitofusin2/ras/raf/MEK pathway gene and protein expression.
Mitofusin 2 may be used as a potential marker for cardiac remodeling and a novel therapeutic target.